Information Provided By:
Fly News Breaks for October 31, 2017
IART
Oct 31, 2017 | 08:08 EDT
UBS analyst Matt Miksic noted Integra LifeSciences delivered disappointing Q3 results and lowered guidance, due partially to storm disruption and slower than expected performance in select product lines. The lowered guidance also takes into account management's slower underlying organic growth rate, which was offset by its Codman acquisition. The analyst still sees significant growth and leverage opportunities and views the pullback as more than discounting the disappointing execution. Miksic maintained his Buy rating and lowered his price target to $57 from $60 on Integra LifeSciences shares.
News For IART From the Last 2 Days
There are no results for your query IART